Re-engineering of the duocarmycin structural architecture enables bioprecursor development targeting CYP1A1 and
Helen M Sheldrake1, Sandra Travica, Inger Johansson
1Institute of Cancer Therapeutics, University of Bradford, Bradford BD7 1DP, UK.
Abstract:
A library of duocarmycin bioprecursors based on the CPI and CBI scaffolds was synthesized and used to probe selective activation by cells expressing CYP1A1 and 2W1, CYPs known to be expressed in high frequency in some tumors. Several CPI-based compounds were pM-nM potent in CYP1A1 expressing cells. CYP2W1 was also shown to sensitize proliferating cells to several compounds, demonstrating its potential as a target for tumor selective activation of duocarmycin bioprecursors.
Related Concept Videos
Drug Discovery: Overview
Drug Biotransformation: Overview
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Prodrugs
Prodrugs help overcome...
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Drug Biotransformation: Overview


